Rare disease drug maker Shire Plc (SHP.L) said on Thursday it had rejected a $63 billion cash-and-stock acquisition offer by Japan’s Takeda Pharmaceutical Co Ltd (4502.T), while Allergan Plc (AGN.N) reversed course on...
Shire sells cancer drugs to Servier for $2.4 billion as Takeda circles
Shire, the London-listed rare diseases specialist that is a potential takeover target for Japan’s Takeda Pharmaceutical, is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion. The deal...
Advent is said to near deal to acquire Sanofi Generics unit
Advent International Corp. is close to acquiring Sanofi’s European generics division in a deal valued at about 2 billion euros ($2.5 billion) including debt, people with knowledge of the matter said. The French...
Takeda sounds out banks for loans as it moves towards Shire bid: sources
Takeda Pharmaceutical (4502.T) has sounded out its major creditors for loans, two sources with direct knowledge of the matter said, as it moves closer to a bid for London-listed rare-disease specialist Shire (SHP.L)...
Corona Remedies acquires specific brand portfolio from Abbott India
Corona Remedies, the Ahmedabad-headquartered mid-sized pharmaceutical firm, has acquired two diabetes and hyperthyroidism brands, Obimet and Thyrocab, comprising 14 product line extensions, from...
ChrysCapital set to acquire 10% in Mankind for $350 million
ChrysCapital, along with limited partners GIC of Singapore and CPPIB of Canada, is set to write the largest private equity cheque in the Indian pharmaceutical space as it finalises a $350-million investment in Mankind...
Orchid gets three final bids at par with liquidation value
Ingen Capital, Fidelity Trading Corporation and Union Quimico Farmacéutica are in the final race to acquire distressed drug maker Orchid Pharma, people familiar with the matter said. The offers made by all of them are...
Lundbeck to buy Parkinson’s drug developer in potential $1.1 billion deal
Lundbeck agreed to buy Prexton Therapeutics, a specialist in treatments for brain disorders, in a deal potentially worth $1.1 billion, the Danish drugmaker said on Friday. Prexton has drug candidate foliglurax in phase...
Torrent Pharma may raise Rs1,500 crore in bid for Sanofi generics business
Torrent Pharma Ltd is likely to raise at least Rs1,500 crore by selling shares to institutional investors, as it prepares a bid for the generic drugs unit of France’s Sanofi, two people aware of the development said...
Torrent Pharma readies €2 billion binding offer for Sanofi’s European unit
Torrent Pharmaceuticals Ltd is readying a €2 billion (Rs16,000 crore) bid for Zentiva N.V., the generic drugs unit of France’s Sanofi, two people directly aware of the bidding process said. If Ahmedabad-based Torrent is...
Carlyle, Advent to submit bids for stake in Mankind Pharma
Private equity funds Carlyle Group and Advent International are poised to submit binding offers to buy a minority stake in Mankind Pharma Ltd, according to two people familiar with the matter. The bids will value the...
Alembic Pharmaceuticals ups its US game plan, acquires Orit
Drug firm Alembic Pharmaceuticals, which is over 100-year-old, started focusing on the US market a bit late. In the past three years, the company has not only increased its research and development (R&D) efforts for...
